BTIG analyst Ryan Zimmerman has maintained their bullish stance on CARL stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ryan Zimmerman has given his Buy rating due to a combination of factors that highlight Carlsmed, Inc.’s strong financial performance and growth potential. The company reported impressive second-quarter results with a significant year-over-year revenue increase, surpassing initial estimates. Carlsmed’s revenue guidance for the fiscal year 2025 is also higher than expected, indicating strong momentum and management’s confidence in achieving these targets.
Additionally, Carlsmed is capitalizing on a substantial market opportunity with its innovative FDA-cleared aprevo platform, which combines AI-driven pre-operative planning with patient-specific implants. The company’s recent IPO has bolstered its capital position, providing a solid financial foundation for future growth. The valuation of Carlsmed is based on a sales estimate that reflects a premium compared to its peers, justified by its rapid growth rate and promising outlook. These factors collectively underpin Zimmerman’s positive outlook and Buy rating for Carlsmed’s stock.
In another report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $16.00 price target.